πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10364258

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10364238

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

KalVista Pharmaceuticals Limited Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10363261

Enolase inhibitors and methods of treatment therewith

The Board of Regents of the University of Texas System Β· Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10358421

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10351532

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10344033

2-aminoquinazoline derivatives as P70S6 kinase inhibitors

SENTINEL ONCOLOGY LIMITED Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10344025

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10342786

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10337005

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

MIRAGEN THERAPEUTICS, INC. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10336773

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10335404

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10335382

Use of hydrogen sulfide synthesis inhibitors for cancer therapy

The Board of Regents of the University of Texas System Β· Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329298

Inhibitors of cellular metabolic processes

Agios Pharmaceuticals, Inc. Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329283

G protein-coupled receptor kinase inhibitors and methods for use of the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329260

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10316371

Screening methods for identifying specific Staphylococcus aureus inhibitors

TRANA DISCOVERY, INC. Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10316038

Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

Aclaris Therapeutics, Inc. Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10315984

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10314908

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to

The United States of America as represented by the Secretary of the Department of Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10308656

Small molecule inhibitors of Ku70/80 and uses thereof

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10308608

Histone deacetylase inhibitors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10308605

Proton pump inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10307423

FBXO3 inhibitors

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10307407

9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted